Key facts
- It has raised $13.0M.
- Notable investors include D11Z.Ventures, Avant Bio, Brightlands Venture Partners, Eurostars, German Accelerator — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for PL BioScience
- ·The full record, as it builds
Funding rounds
No funding rounds for PL BioScience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PL BioScience
Operator of a biotech platform designed to provide animal-component-free supplements for cell growth. The company offers human-derived and fully lab-made platelet lysate products, produced under rigorous standards to meet the growing demand for cell culture media for all phases of research and development with stem cells, enabling researchers and manufacturers in regenerative medicine, cell therapy, and biopharmaceutical development to access safer, ethically sourced, and scalable cell culture supplements.
- Sector
- Healthcare
- HQ
- Aachen, Germany
- Founded
- 2015
- Employees
- 28
- Website
- pl-bioscience.com/
- Ownership
- Privately Held (backing)
PL BioScience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PL BioScience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PL BioScience in its N-PORT filings yet. We sweep new filings monthly.